Venetoclax plus bortezomib and dexamethasone improved PFS in relapsed/refractory multiple myeloma, especially in patients with BCL2high disease.
Tim Cortese
Advertisement
Articles by Tim Cortese
Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
SGLT2 Inhibitors Tied to Lower Platelet Activation in HFrEF
3
Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups
4
FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance
5